LEEDS, England - April 30, 2018 - Amzeal -- According to our sources, Intellipharmaceutics International Inc. (IPCI) will be announcing an International partnership with a Chinese pharmaceutical company soon. IPCI will be getting all their presently FDA approved drugs manufactured and sold to the Asian markets, along with any recent FDA approvals that may come at any given time.

It seems that IPCI will not stop at just Asia but will also be working on other International markets with the soon to be proposed director of international affairs for IPCI which seems to be a great asset to IPCI. The proposed director Shawn Graham was with Dr. Odidi for the Chinese inauguration of the new partnership. Mr. Graham is also CEO of G&R Holdings Inc. G&R Holdings Inc. is one of Canada's leading companies in developing and implementing business alliances and partnerships between Chinese and Canadian companies. IPCI has been setting up a partnership with a Chinese pharmaceutical company.

The final details are being ironed out according to our sources and full production along with sales of all IPCI's FDA products shall soon be selling to the Asian markets bringing profits back to IPCI shareholders. Moving forward with the Chinese deal IPCI was strongly advised to get a secure IT network. Therefore IPCI has used Pulse Tech Corporation, a custom IT upgrade support and service provider has taken on the job to upgrade and strengthen and fully integrate IPCI's system. This will optimize the strength of its IT security in dealing with its foreign partner with data security. IPCI will soon have its security of the utmost best to deal with its new Asian partner by having the following: 3 layer multi-location backup, new hardware and software operating system and finally a multi data load balancing system with additional network and data security.

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development, and manufacture of novel and generic controlled- and targeted release oral solid dosage drugs. The Company's patented Hypermatrix™ technology is a multidimensional controlled-release drug delivery platform that can be applied to a wide range of existing and new pharmaceuticals. Intellipharmaceutics has developed several drug delivery systems based on this technology platform, with a pipeline of products (some of which have received FDA approval) in various stages of development. The Company has Abbreviated New Drug Application ("ANDA") and NDA 505(b)(2) drug product candidates in its development pipeline. These include Oxycodone ER abuse-deterrent oxycodone formulation based on its proprietary nPODDDS™ novel Point Of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin™ XR (pregabalin extended-release capsules).